Addition of Sintilimab to Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer

1. SPRING-01 trial assessed sintilimab with chemotherapy after radiotherapy. 2. 98 patients were randomized into two groups. 3. Pathologic complete response rate: 59.2% (sintilimab) vs 32.7% (control). 4. Adverse events included thrombocytopenia, leukopenia, and anemia. 5. Grade 3 to 4 events were similar in both groups. 6. No treatment-related deaths occurred. 7. Findings indicate efficacy and safety of this treatment regimen.